Arcus Biosciences, Inc. (RCUS)

NYSE: RCUS · IEX Real-Time Price · USD
23.13
+0.04 (0.17%)
At close: Jan 27, 2023, 4:00 PM
23.90
+0.77 (3.33%)
After-hours: Jan 27, 2023, 7:11 PM EST
0.17%
Market Cap 1.67B
Revenue (ttm) 432.84M
Net Income (ttm) 79.82M
Shares Out 72.41M
EPS (ttm) 1.20
PE Ratio 19.28
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 957,677
Open 23.05
Previous Close 23.09
Day's Range 22.66 - 23.63
52-Week Range 16.74 - 39.75
Beta 0.86
Analysts Buy
Price Target 44.29 (+91.48%)
Earnings Date Feb 22, 2023

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combinatio... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Terry J. Rosen Ph.D.
Employees 366
Stock Exchange NYSE
Ticker Symbol RCUS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for RCUS stock is "Buy." The 12-month stock price forecast is $44.29, which is an increase of 91.48% from the latest price.

Price Target
$44.29
(91.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compen...

3 days ago - Business Wire

Down -45.21% in 4 Weeks, Here's Why Arcus Biosciences, Inc. (RCUS) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St...

2 weeks ago - Zacks Investment Research

Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug

Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that ...

Other symbols: GILD
1 month ago - Market Watch

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analys...

Other symbols: GILD
1 month ago - Business Wire

Wall Street Analysts Believe Arcus Biosciences, Inc. (RCUS) Could Rally 45%: Here's is How to Trade

The consensus price target hints at a 44.5% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

2 months ago - Zacks Investment Research

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of ...

Other symbols: GILD
2 months ago - Business Wire

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of ...

Other symbols: GILD
2 months ago - Business Wire

Arcus Biosciences to Participate in the 5th Annual Evercore ISI HealthCONx Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for peopl...

2 months ago - Business Wire

Wall Street Analysts See a 75% Upside in Arcus Biosciences, Inc. (RCUS): Can the Stock Really Move This High?

The consensus price target hints at a 75% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn...

2 months ago - Zacks Investment Research

Buy 3 of the Best Stocks by Using Net Income Ratio

Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.

Other symbols: CMRXVIST
3 months ago - Zacks Investment Research

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 14.29% and 83.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...

3 months ago - Zacks Investment Research

Can Arcus Biosciences, Inc. (RCUS) Climb 75% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 74.8% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

3 months ago - Zacks Investment Research

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...

5 months ago - Business Wire

Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

6 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 0% and 27.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

6 months ago - Business Wire

Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...

6 months ago - Business Wire

Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...

8 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -215.66% and 88.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto...

9 months ago - Zacks Investment Research

Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

9 months ago - Business Wire

Arcus Biosciences to Report First Quarter 2022 Financial Results and Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...

9 months ago - Business Wire

4 Undervalued Biotech Stocks to Add to Your Buy List

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

Other symbols: BEAMBNTXVIR
10 months ago - InvestorPlace

Arcus shares jump 13% after announcing plans to join S&P SmallCap 600

Shares of Arcus Biosciences Inc. RCUS, +9.07% gained 13.1% in premarket trading on Tuesday after the company said it is set to join the S&P SmallCap 600 SML, -0.38% before the market opens on Thursday...

10 months ago - Market Watch

Arcus Biosciences Set to Join S&P SmallCap 600

NEW YORK , April 4, 2022 /PRNewswire/ -- Arcus Biosciences Inc. (NYSE:RCUS) will replace Investors Bancorp Inc. (NASD:ISBC) in the S&P SmallCap 600 effective prior to the opening of trading on Thursda...

Other symbols: CFG
10 months ago - PRNewsWire